ALK (Anaplastic Lymphoma Kinase)
ALK
Receptor tyrosine kinase rearranged in ~5% of NSCLC.
Função
ALK inhibitors (crizotinib, alectinib, lorlatinib) achieve high response rates in ALK-rearranged NSCLC.
ALK
Receptor tyrosine kinase rearranged in ~5% of NSCLC.
ALK inhibitors (crizotinib, alectinib, lorlatinib) achieve high response rates in ALK-rearranged NSCLC.